Sci-Tech-Prod (Science-Technology-Products) Village: 科學技術產品村: 024
惠普噴墨技術化身藥劑貼布
received from Pi-Twan Huang 黃碧端
http://www.ithome.com.tw/itadm/article.php?c=45265
文/陳曉莉 (編譯) 2007-09-12

惠普說明,透過遍布在貼布上的數百個微小針頭,將能提供多種不同的藥劑,應用在各
種醫療領域上。。

惠普(HP)在周二(9/11)宣布授權愛爾蘭的醫療設備開發商Crospon印表機技術作為藥
物傳送平台,利用惠普的噴墨專利技術提供無痛的貼布。

該採用惠普專利的醫療貼布是由惠普實驗室所發明,由Crospon負責商業化,預計可在三
年內通過美國食品與醫藥管理局的核准上市。

由惠普所開發的皮膚貼布上採用了許多剛好可滲透皮膚的微型針頭,以減少痛楚,同時
這些微型針頭也可以程式化,設計在何時注射多少的藥量,並且能夠在不同的微型針頭
上提供不同的藥劑。

過去的皮膚貼布多半是透過皮膚吸收,並且成為癮君子戒煙方式的主流,但這些貼布通
常只能提供一種藥劑,惠普說明,透過遍布在貼布上的數百個微小針頭,將能提供多種
不同的藥劑,應用在各種醫療領域上。

惠普一開始開發藥劑傳送技術是打算將噴墨技術運用在新的市場上,而在皮膚貼布上採
用的技術則是類似惠普在噴墨墨水匣的專利程序。

Crospon執行長John O’Dea指出,由惠普所發明的、該產業第一個皮膚貼布可讓Crospon
提供病人及醫生最高階的藥物傳送平台,他們將會與醫藥客戶共同將此一突破性的解決
方案推向市場。(編譯/陳曉莉)  
Crospon Licenses HP Technology to Create Industry-first
Skin Patch for “Smart” Drug Delivery
received from Pi-Twan Huang 黃碧端
http://www.hp.com/hpinfo/newsroom/press/2007/070911a.html
Fusion of high-tech and biotech improves safety, efficacy and ease-of-use for
patients

PALO ALTO, Calif., Sept. 11, 2007
--------------------------------------------------------------------------------

HP and Crospon, a medical device developer based in Galway, Ireland, today
announced they have entered a licensing agreement for a drug delivery platform that
enables painless, controlled release of one or more drugs in a single patch applied
to the skin.

Under the agreement, HP will license its intellectual property to Crospon in return
for royalty payments. Crospon will commercialize the patch, which was invented by
HP Labs, the company’s central research facility, and make it available to
pharmaceutical companies to use in various therapeutic areas.

Crospon, which recently announced the finalization of €2.3 million in seed financing,
will manufacture the skin patch and manage all marketing, sales and support of the
technology.

The patch delivers medication intradermally – just below the surface of the skin –
and enables precise control of dosage timing, access to dosage history, patient
activation mechanisms and inherent safety protocols for preventing adverse drug
interactions.

Transdermal patches (which rely on absorption through the skin) for nicotine
delivery have become a mainstay for smoking cessation programs; however, they
have not been a widely effective delivery mechanism for many drugs because the
skin acts as a natural barrier.
The HP-developed skin patch uses microneedles that barely penetrate the skin; this radically reduces discomfort compared to traditional hypodermic needles and enables
the technique to be used with a much wider variety of drugs and biopharmaceuticals. The microneedles allow medication to quickly enter the bloodstream, resulting in the
potential delivery of lower and more precise dosages.

HP initially developed the drug delivery technology as a way to repurpose its inkjet technology for use in new markets. The technology in the skin patch is similar to that
employed in HP’s patented process for its inkjet cartridges.

“This industry-first skin patch invented by HP allows Crospon to offer a superior drug delivery platform for doctors and patients,” said John O’Dea, chief executive officer,
Crospon. “We look forward to working with our pharmaceutical customers to bring this breakthrough solution to the market.”

The agreement between HP and Crospon resulted in part from HP’s relationship with Enterprise Ireland, an Irish government agency tasked with supporting and growing
indigenous business in Ireland. Through Enterprise Ireland, companies can license the intellectual property of HP and access the company’s business and technology
mentoring.

“We encourage companies like Crospon to apply HP’s intellectual property in innovative ways to help more people benefit from these important technologies,” said Joe
Beyers, vice president, Intellectual Property Licensing, HP. “By licensing core intellectual property in thermal inkjet technology for use in a drug delivery product, HP breathes
new life into its mature technology while capitalizing on the booming healthcare and life sciences market.”

HP encourages other organizations worldwide to leverage its vast research and development network and portfolio of nearly 30,000 patents to bring new technologies to
market through intellectual property licensing agreements. These agreements also enable HP to generate a return on its R&D investment through licensing fees and
royalties.

More information on HP’s intellectual property licensing program is available at www.hp.com/hpinfo/abouthp/iplicensing/.

Images of the prototype drug delivery platform are available at www.hpl.hp.com/about/media/drug_delivery/.

About Crospon

Crospon, formed in 2006, is a medical device company focused on the monitoring and treatment of diabetes and gastroesophageal reflux disorder (GERD). Crospon
recently announced the closure of a €2.3 million seed round of financing, which included investment by Enterprise Ireland and The Western Development Commission (
www.crospon.com). Company founder and Chief Executive Officer John O’Dea, previously co-founded Caradyne, a Galway, Ireland-based respiratory products company that
was acquired by Respironics Inc. in 2004.

About HP

HP focuses on simplifying technology experiences for all of its customers – from individual consumers to the largest businesses. With a portfolio that spans printing,
personal computing, software, services and IT infrastructure, HP is among the world’s largest IT companies, with revenue totaling $100.5 billion for the four fiscal quarters
ended July 31, 2007. More information about HP (NYSE: HPQ) is available at www.hp.com.
Click to go to companion website:
Google